Multicenter phase 2 trial of neoadjuvant-adjuvant versus adjuvant-only pembrolizumab for advanced melanoma
Dr. Sapna Patel
A multicenter phase 2 trial in the USA found that among patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone (quick take video summary).
